Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions-Reference-Cited by-同舟云学术

Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions

Published:2023-06 Issue: Volume:129 Page:107072
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Moore Jeremiah E.,Bloom Paige C.,Chu Charles C.,Bruno Jennifer E.,Herne Christine A.,Baran Andrea M.,Quataert Sally A.,Mosmann Timothy R.,Taylor Ronald P.,Wallace Danielle S.,Elliott Michael R.,Barr Paul M.,Zent Clive S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference45 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N. Engl. J. Med.,2002

2. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma;Habermann;J. Clin. Oncol.,2006

3. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia;Schulz;Blood,2002

4. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

5. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma;Marcus;Blood,2005

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody‐mediated phagocytosis in cancer immunotherapy;Immunological Reviews;2023-08-21

2. A novel prednisone premedication protocol significantly decreases infusion‑related reactions of rituximab in newly diagnosed diffuse large B‑cell lymphoma;Oncology Letters;2023-04-28